Akash Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 09-12-2024
- Paid Up Capital ₹ 3.72 M
as on 09-12-2024
- Company Age 45 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.90 M
as on 09-12-2024
- Revenue -58.31%
(FY 2022)
- Profit 1632.56%
(FY 2022)
- Ebitda -1406.12%
(FY 2022)
- Net Worth 3.72%
(FY 2022)
- Total Assets 4.44%
(FY 2022)
About Akash Pharma
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 3.72 M.
The company currently has active open charges totaling ₹0.90 M.
Pradeep Jain and Arihant Jain serve as directors at the Company.
- CIN/LLPIN
U24232AS1979PTC001772
- Company No.
001772
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 May 1979
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Shillong
Industry
Company Details
- Location
Kamrup, Assam, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Akash Pharma Pvt Ltd offer?
Akash Pharma Pvt Ltd offers a wide range of products and services, including TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Sexual Wellness Products, Erectile Dysfunction Medicine, Brain & Nervous System Drugs, Antiepileptic Drugs, Cardiovascular Drugs & Medication, Diabetes Medicine, Antidepressant & Anti Anxiety Medicines, Anticoagulant and Antiplatelet Drugs.
Who are the key members and board of directors at Akash Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pradeep Jain  | Director | 30-Mar-2016 | Current |
| Arihant Jain | Director | 28-Oct-2017 | Current |
Financial Performance of Akash Pharma.
Akash Pharma Pvt Ltd, for the financial year ended 2022, experienced significant reduction in revenue, with a 58.31% decrease. The company also saw a substantial improvement in profitability, with a 1632.56% increase in profit. The company's net worth moved up by a moderate rise of 3.72%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Akash Pharma?
In 2022, Akash Pharma had a public holding of 61.94%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Syndicate Bank Creation Date: 31 Oct 1994 | ₹0.30 M | Open |
Syndicate Bank Creation Date: 12 Mar 1993 | ₹0.30 M | Open |
Syndicate Bank Creation Date: 12 Mar 1981 | ₹0.30 M | Open |
How Many Employees Work at Akash Pharma?
Unlock and access historical data on people associated with Akash Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Akash Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Akash Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
